Pages that link to "Q40585257"
Jump to navigation
Jump to search
The following pages link to The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. (Q40585257):
Displaying 50 items.
- The central GLP-1: implications for food and drug reward (Q21129358) (← links)
- Prolactin-releasing peptide: a new tool for obesity treatment (Q26740249) (← links)
- Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors (Q26770832) (← links)
- Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease (Q26827183) (← links)
- Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review (Q27010547) (← links)
- Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics (Q27027238) (← links)
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (Q28273497) (← links)
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus (Q30249371) (← links)
- The entero-insular axis: implications for human metabolism. (Q30365939) (← links)
- Gut peptides and type 2 diabetes mellitus treatment (Q31157033) (← links)
- Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). (Q33224640) (← links)
- Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model (Q33486125) (← links)
- Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists (Q33521451) (← links)
- Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes (Q33585560) (← links)
- Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide (Q33608023) (← links)
- Role and development of GLP-1 receptor agonists in the management of diabetes. (Q33635830) (← links)
- Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs (Q33664253) (← links)
- GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly? (Q33734024) (← links)
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults (Q33737073) (← links)
- Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives (Q33755744) (← links)
- Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. (Q33785308) (← links)
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) (Q33854032) (← links)
- The evolving place of incretin-based therapies in type 2 diabetes (Q33866808) (← links)
- Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years (Q33884913) (← links)
- Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus (Q34026346) (← links)
- Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides (Q34128861) (← links)
- Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study (Q34202922) (← links)
- Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes. (Q34214488) (← links)
- Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial (Q34284003) (← links)
- Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. (Q34381400) (← links)
- Glucagon-like peptide 1(GLP-1) in biology and pathology (Q34401791) (← links)
- Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation (Q34405101) (← links)
- Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment (Q34407868) (← links)
- Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus (Q34496741) (← links)
- Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study (Q34598940) (← links)
- Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. (Q34620493) (← links)
- Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes (Q34648201) (← links)
- Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide (Q34659509) (← links)
- Incretin-based therapies in prediabetes: Current evidence and future perspectives (Q34699191) (← links)
- The role of incretins in glucose homeostasis and diabetes treatment (Q34901533) (← links)
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). (Q34986024) (← links)
- Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients (Q35080171) (← links)
- Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line (α-TC1): evidence of a direct effect of GLP-1 on pancreatic alpha cells (Q35108666) (← links)
- Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. (Q35110843) (← links)
- GLP-1 based therapeutics: simultaneously combating T2DM and obesity. (Q35200252) (← links)
- Enhancing Incretin Action for the Treatment of Type 2 Diabetes (Q35545683) (← links)
- Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis (Q35666210) (← links)
- Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes (Q35677365) (← links)
- Gut peptides in the treatment of diabetes mellitus (Q35688209) (← links)
- Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats (Q35757217) (← links)